AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05840276 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
Study NCT06026358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirbanibulin
Description: subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
Study NCT06026358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin
Description: subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
Study NCT05639023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation Techniques
Description: Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
Study NCT05639023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Scoliosis-Specific Exercise
Description: Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
Study NCT05165069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin 5 MG Disintegrating Oral Tablet
Description: Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
Study NCT05165069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
Study NCT05784155 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Test Drug(JW0302) or Reference Drug(C2206)
Description: Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Study NCT05462483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Sock and Instructions to heat the quadriceps.
Description: A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
Study NCT06048055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
Study NCT06048055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
Study NCT06048055 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: selected physical therapy program
Description: The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
Study NCT06378372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy based on piano learning
Description: The intervention will consist of pianistic training. Patients will receive piano classes adapted to their competence designed to achieve motor, sensory and behavioral control.
Study NCT04832971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG3
Description: ARO-ANG3 Injection
Study NCT04921761 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional epidural
Description: In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
Study NCT04832971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARO-ANG3
Description: ARO-ANG3 Injection
Study NCT04832971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl)
Study NCT06077929 — intervention group
Intervention type: OTHER
Intervention: No intervention done
Description: No interventions done
Study NCT05290233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRE + Exercise
Description: We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise
Study NCT05290233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE + Exercise
Description: We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise
Study NCT05321875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
Study NCT05321875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan
Description: 3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
Study NCT06078540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USeeBP
Description: USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;
Study NCT04921761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
Study NCT06109857 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06478043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivonescimab
Description: 20mg/kg, IV, D1, Q3W
Study NCT06478043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome
Description: 56.5mg/m\^2, IV, D1, Q2W
Study NCT06272201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors
Description: POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
Study NCT05212519 — intervention group
Intervention type: OTHER
Description: For observational research
Study NCT06509139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT06509139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT06288919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol prophylactic powders
Description: erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
Study NCT06288919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scaler with peek inserts
Description: ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
Study NCT06043271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EMPOWER Program
Description: The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
Study NCT05203172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib only treatment
Description: Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
Study NCT05203172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib only Treatment
Description: Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
Study NCT05203172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib & Binimetinib Treatment
Description: Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
Study NCT05203172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Encorafenib & Binimetinib & Ribociclib
Description: Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
Study NCT05203172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Encorafenib & Binimetinib & Cetuximab
Description: Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
Study NCT05158192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin/Hesperidin (90/10) 500 mg Test Drug
Description: Investigational Medicinal Product
Study NCT05158192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin/Hesperidin (90/10) 500 mg Reference Product
Description: Daflon (Trademark)
Study NCT06509139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT06509139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT05276024 — intervention group
Intervention type: DEVICE
Intervention: iFuse Bedrock technique
Description: Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
Study NCT04263831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (aldesleukin).
Description: Description of intervention is covered in Arm, above.
Study NCT05927584 — intervention group
Intervention type: PROCEDURE
Intervention: Transanal local excision
Description: Transanal full thickness local excision
Study NCT04543838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
Study NCT04543838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care BP management
Description: If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
Study NCT04067752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dialysate sodium concentration (138 mEq/L)
Description: high dialysate sodium concentration (138 mEq/L)
Study NCT04067752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dialysate sodium concentration
Description: low dialysate sodium concentration (132 mEq/L)
Study NCT05663502 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and/or tumor tissue sample collection
Study NCT05602870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)
Description: A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
Study NCT05438888 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
Study NCT05438888 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
Study NCT04845477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic tape
Description: magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
Study NCT04845477 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology tape
Description: kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
Study NCT06061341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TruGraf®
Description: TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
Study NCT06677021 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Physical activity promotion and engagement
Study NCT06681610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation
Description: low intensity shock-waves stimulation of the motor cortex, bilateral
Study NCT06681610 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulse Stimulation
Description: low intensity shock-waves stimulation of the motor cortex, bilateral
Study NCT06680544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole high dose
Description: Oral voriconazole 200mg once a day for a maximum of 28 days
Study NCT06680544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole low dose
Description: Oral voriconazole 200mg twice a day for a maximum of 28 days
Study NCT06681805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine + Bupivacaine + Morphine
Description: Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.
Study NCT06681805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine + Bupivacaine + Morphine
Description: Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
Study NCT06681805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Bupivacaine + Morphine
Description: Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.
Study NCT06681805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Bupivacaine + Morphine
Description: Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
Study NCT06681298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The experimental group received Nivolumab
Description: Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
Study NCT06681298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The experimental group received Nivolumab
Description: Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
Study NCT05215886 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surgery
Description: Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
Study NCT06289985 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular thrombectomy with any FDA-approved category POL or NRY device
Description: Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)
Study NCT06289985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Management
Description: Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.
Study NCT06679894 — intervention group
Intervention type: PROCEDURE
Intervention: Implant site preparation with osteotomes and electrified mallet
Description: Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~A pilot osteotome (100-P) was used to easily perforate the cortical plate. Subsequently, osteotomes with gradually increasing diameters were employed until the final diameter of 3.2 mm was reached.~The sequence of osteotomes and their respective diameters were as follows:~1. Osteotome 100-P: At a height of 8.5 mm, the diameter was 2.2 mm;~2. Osteotome 160: At a height of 8.5 mm, the diameter was 2.8 mm;~3. Osteotome 200: At a height of 8.5 mm, the diameter was 3.2 mm. Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment.
Study NCT06679894 — intervention group
Intervention type: PROCEDURE
Intervention: Implant site preparation with osseodensification drills
Description: Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~The implant site preparation was realized using osseodensification burs at a rotation speed of 1200 rpm. The osseodensification burs sequence was as follows:~1. Initial pilot hole (rotated clockwise);~2. WT1828 bur (rotated counterclockwise),~3. WT2838 bur (rotated counterclockwise). Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment.
Study NCT06680765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
Study NCT06680765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison group
Description: These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).